CEACAM5

Our CEACAM5 CAR-T products and services are designed to help researchers and biopharmaceutical companies accelerate their development of innovative cancer immunotherapies. Please find the appropriate products you need.

Background

CEACAM5, also known as carcinoembryonic antigen-related cell adhesion molecule 5, is a cell surface glycoprotein that plays a critical role in various human tumors, including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), breast cancer, and neuro-endocrine prostate cancer (NEPC). Overexpression of CEACAM5 has been associated with tumor differentiation, invasion, and metastasis in these cancers. Therapies targeting CEACAM5, such as CAR-T cells, have shown promising results in combating cancer cells expressing CEACAM5.

Fig.1 Expressions of CEACAM5 in different normal or tumor tissues.¹

Associated Disease

• Non-small cell lung cancer (NSCLC)
• Pancreatic ductal adenocarcinoma (PDAC)
• Breast cancer
• Neuro-endocrine prostate cancer (NEPC)

Anti-CEACAM5 CAR-T Services

Anti-CEACAM5 CAR-T In Vitro Assays

• Anti-CEACAM5 CAR-T Expression Test

Creative Biolabs has developed a variety of methods to confirm the expression of chimeric antigen receptors on engineered CART cells, such as flow cytometry, WB, etc. Flow cytometry is the more common approach, in which CAR target antigens are linked to fluorescent tags such as PE or APC for direct detection. This method is favored for its low background noise and high specificity for CAR proteins. In addition, universal detection using linker antibodies, or anti-mouse/human Fab antibodies provides an alternative method for CAR detection and quantification.

• Anti-CEACAM5 CAR-T Characterization Analysis

Phenotype testing of CAR-T cells serves as a crucial step in assessing the function of CART cells. This testing involves characterizing the expression of surface markers, and functional molecules on the engineered T cells. Creative Biolabs has launched comprehensive characterization testing for CAR-T cells to evaluate the presence of other surface markers associated with T cell activation, differentiation, exhaustion, memory formation, etc. This analysis will provide insights into the functionality and behavior of the CAR-T cells in vitro.

• Anti-CEACAM5 CAR-T In Vitro Cytotoxicity Assay

In vitro cytotoxicity assays are crucial during early CART development and optimization, which provide valuable insights into the mechanism of action, efficacy, and specificity of the treatment. Creative Biolabs provides sensitive cytotoxicity detections based on several approaches, including RTAC analysis, LDH detection, and flow cytometry.

Fig.2 In vitro cytotoxicity of anti-CEACAM5 CAR-T cells against different tumor cells at indicated E:T ratio.¹

Anti-CEACAM5 CAR-T In Vivo Assays

• Therapy Model for Anti-CEACAM5 CAR-T

The choice of animal model for CART in vivo study is crucial and should reflect the intended clinical application of the therapy. Different models such as xenograft, humanized, syngeneic, and transgenic models can provide insights into various aspects of CAR-T cell therapy, including efficacy, toxicity, and specificity. For example, xenograft models involving immunocompromised mice injected with human tumor cells can be valuable for evaluating the antitumor activity of CAR-T cells. We offer a variety of animal models for customers to choose the appropriate model for CART in vivo experiments.

Fig.3 Schematic representation of Anti-CEACAM5 CAR-T in vivo experimental design.¹

• Anti-CEACAM5 CAR-T In Vivo Efficacy Assay

In vitro cytotoxicity assays are crucial during early CART development and optimization, which provide valuable insights into the mechanism of action, efficacy, and specificity of the treatment. Creative Biolabs provides one-stop in vivo study service with evaluation of multiple parameters such as tumor growth inhibition, tumor regression, cytokine release, and potential off-target effects on healthy tissues. By carefully monitoring these factors in relevant animal models, researchers can better understand the therapeutic potential and safety of CAR-T cell therapy before proceeding to clinical trials.

Fig.4 In vivo efficacy of anti-CEACAM5 CAR-T cells in the A549-CEACAM5 CDX models. (B) Tumor growth curve of CDX models with the CAR-T treatment. (C) Survival curve of CDX model with the CAR-T treatment.¹

Reference

1. Kim, Ye-Jin, et al. "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates." Frontiers in Oncology 13 (2023): 1124039.